Viromed Medical AG Plans Share Placements to Bolster Financing

Viromed Medical AG, a leader in cold plasma technology, announces plans for additional share placements from CEO Uwe Perbandt’s holdings. The sales aim to generate funds for ongoing operations and enhance working capital. This move follows a previous 1.7 million euros contribution from the Perbandt family, supporting the company's financial needs and regulatory activities.

Uwe Perbandt emphasizes the intention to prepare for growth by increasing purchase volumes and inventory size. The strategy includes involving new investors to expand Viromed's investor base. Perbandt plans to reduce his family’s stake in the company to 25.1%, facilitating the acquisition of relyon plasma GmbH.

These reallocations will target strategic investors, aiming for minimal impact on the share price while contributing to Viromed's strategic development and cold plasma technology goals.